STAT+: Why Marty Makary Was the Worst FDA Commissioner in 25 Years

Why It Matters

Leadership instability at the FDA can stall drug approvals, erode industry confidence, and reshape regulatory priorities, affecting billions in pharmaceutical investment.

Key Takeaways

• Makary resigned after pressure from FDA staff and lawmakers.
• Senior leadership turnover rose sharply during his tenure.
• Agency standards were perceived as weakened under his direction.
• AI and faster review processes were his notable initiatives.
• Instability may delay drug approvals and affect industry confidence.

Pulse Analysis

The FDA commissioner’s role is a linchpin for public health and the multi‑billion‑dollar pharmaceutical sector. Marty Makary, a surgeon‑turned regulator, entered the post with a reputation for data‑driven advocacy but quickly ran afoul of the agency’s culture. Within a year, senior officials either left or were dismissed, and internal surveys reflected a loss of confidence in his strategic vision. His resignation, prompted by bipartisan pressure, marks the first forced exit of an FDA chief in a quarter‑century and raises questions about governance at the nation’s most powerful drug‑approval body.

Critics argue that Makary’s tenure weakened the FDA’s regulatory rigor. By prioritizing rapid “wins,” such as cutting dead‑time in reviewer feedback, he inadvertently lowered the bar for evidence review, prompting concerns among scientists and industry insiders. The exodus of seasoned leaders further eroded institutional memory, while staff reported feeling sidelined when their expertise on complex scientific and political nuances was ignored. These missteps contributed to a perception that the agency’s standards were compromised, potentially jeopardizing the safety net that protects consumers from inadequately vetted therapies.

Despite the fallout, Makary’s push for artificial‑intelligence integration and accelerated clinical‑trial pathways highlighted a growing demand for modernization. If harnessed correctly, AI can streamline drug discovery, and faster trial designs can bring life‑saving treatments to market sooner. However, the episode underscores that technological ambition must be balanced with stable, experienced leadership. As the FDA appoints an acting commissioner, industry stakeholders will watch closely for signals that the agency can restore credibility while still pursuing innovation, a balance critical to maintaining investor confidence and public trust.